J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270007310382v1
48/2/209    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwamoto, M.
Right arrow Articles by Wagner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwamoto, M.
Right arrow Articles by Wagner, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

DRUG INTERACTIONS

Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation

Marian Iwamoto, MD, PhD, Kelem Kassahun, PhD, Matthew D. Troyer, MD, William D. Hanley, PhD, Ping Lu, MS, Alisha Rhoton, BS, Amelia S. Petry, BS, Kalyan Ghosh, PhD, Eric Mangin, BS, Emanuel P. DeNoia, MD, Larissa A. Wenning, PhD, Julie A. Stone, PhD, Keith M. Gottesdiener, MD and John A. Wagner, MD, PhD

From Merck & Co, Inc, Whitehouse Station, New Jersey (Dr Iwamoto, Dr Kassahun, Dr Troyer, Dr Hanley, Ms Lu, Ms Rhoton, Ms Petry, Dr Ghosh, Mr Mangin, Dr Wenning, Dr Stone, Dr Gottesdiener, Dr Wagner) and Healthcare Discoveries, Inc, San Antonio, Texas (Dr DeNoia).

Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum). In vitro characterization of raltegravir inhibition potential was assessed against a panel of cytochrome P450 (CYP) enzymes. An open-label, 2-period study was conducted to assess the effect of raltegravir on the pharmacokinetics of midazolam, a sensitive CYP 3A4 probe substrate: period 1, 2.0 mg of midazolam; period 2, 400 mg of raltegravir every 12 hours for 14 days with 2.0 mg of midazolam on day 14. There was no meaningful in vitro effect of raltegravir on inhibition of a panel of CYP enzymes and induction of CYP 3A4. In the presence of raltegravir, midazolam area under the curve extrapolated to infinity (AUC0-{infty}) and maximum plasma concentration (Cmax) geometric mean ratios were similar (geometric mean ratios and 90% confidence intervals: 0.92 [0.82, 1.03] (P = .208) and 1.03 [0.87, 1.22] (P = .751), respectively). No substantial differences were observed in Tmax (P = .750) or apparent half-life (P = .533) of midazolam. Plasma levels of midazolam were not substantially affected by raltegravir, which implies that raltegravir is not a clinically important inducer or inhibitor of CYP 3A4 and that raltegravir would not be expected to affect the pharmacokinetics of other drugs metabolized by CYP 3A4 to a clinically meaningful extent.

Key Words: Raltegravir • HIV-1 integrase inhibitor • pharmacokinetics • midazolam • drug interaction

Address for correspondence: Marian Iwamoto, MD, PhD, Merck & Co, Inc, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
W. D. Hanley, L. A. Wenning, A. Moreau, J. T. Kost, E. Mangin, T. Shamp, J. A. Stone, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto
Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2752 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. A. Wenning, W. D. Hanley, D. M. Brainard, A. S. Petry, K. Ghosh, B. Jin, E. Mangin, T. C. Marbury, J. K. Berg, J. A. Chodakewitz, et al.
Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2852 - 2856.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Iwamoto, L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Breidinger, E. C. Mangin, N. Azrolan, H. E. Greenberg, et al.
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4338 - 4343.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. S. Anderson, T. N. Kakuda, W. Hanley, J. Miller, J. T. Kost, R. Stoltz, L. A. Wenning, J. A. Stone, R. M. W. Hoetelmans, J. A. Wagner, et al.
Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4228 - 4232.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology